Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Debt to Equity (2020 - 2026)

GeneDx Holdings has reported Debt to Equity over the past 7 years, most recently at $0.38 for Q1 2026.

  • Quarterly Debt to Equity rose 89.17% to $0.38 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $0.38 through Mar 2026, up 89.17% year-over-year, with the annual reading at $0.16 for FY2025, 26.15% down from the prior year.
  • Debt to Equity was $0.38 for Q1 2026 at GeneDx Holdings, up from $0.16 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.38 in Q1 2026 and troughed at $0.02 in Q2 2022.
  • The 5-year median for Debt to Equity is $0.18 (2025), against an average of $0.15.
  • Year-over-year, Debt to Equity soared 1173.55% in 2024 and then crashed 30.64% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $0.04 in 2022, then surged by 495.59% to $0.23 in 2023, then dropped by 8.39% to $0.21 in 2024, then decreased by 26.15% to $0.16 in 2025, then skyrocketed by 143.5% to $0.38 in 2026.
  • Per Business Quant, the three most recent readings for WGS's Debt to Equity are $0.38 (Q1 2026), $0.16 (Q4 2025), and $0.18 (Q3 2025).